Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Minimal Residual Disease Negativity”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Testing effectiveness (Phase 2)WithdrawnNCT03515707
What this trial is testing

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaMinimal Residual Disease Negativity
Fred Hutchinson Cancer Center
Large-scale testing (Phase 3)Looking for participantsNCT04513639
What this trial is testing

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Who this might be right for
Multiple Myeloma
Oslo University Hospital 176
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Testing effectiveness (Phase 2)UnknownNCT01521689
What this trial is testing

Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment

Who this might be right for
Chronic Lymphocytic Leukemia
Institut Paoli-Calmettes 35
Large-scale testing (Phase 3)Active Not RecruitingNCT03267433
What this trial is testing

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Who this might be right for
Mantle Cell Lymphoma
ECOG-ACRIN Cancer Research Group 689
Not applicableUnknownNCT05339204
What this trial is testing

The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

Who this might be right for
AML
National Research Center for Hematology, Russia 75
Not applicableLooking for participantsNCT07003737
What this trial is testing

Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation

Who this might be right for
Acute Lymphoblastic Leukemia, B-precursor
First Affiliated Hospital of Zhejiang University 114
Testing effectiveness (Phase 2)WithdrawnNCT06903702
What this trial is testing

Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
Not applicableLooking for participantsNCT06463717
What this trial is testing

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Who this might be right for
Multiple MyelomaMinimal Residual Disease
First Affiliated Hospital of Zhejiang University 210
Testing effectiveness (Phase 2)Looking for participantsNCT06910124
What this trial is testing

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

Who this might be right for
Multiple Myeloma
Dickran Kazandjian, MD 32
Not applicableLooking for participantsNCT05866757
What this trial is testing

Discontinuation Study

Who this might be right for
Multiple MyelomaCancerHematologic Cancer
University College Cork 70
Testing effectiveness (Phase 2)Looking for participantsNCT06376526
What this trial is testing

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Dickran Kazandjian, MD 150
Testing effectiveness (Phase 2)Looking for participantsNCT07407920
What this trial is testing

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2-Positive Breast Carcinoma+1 more
M.D. Anderson Cancer Center 120
Not applicableActive Not RecruitingNCT04221178
What this trial is testing

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

Who this might be right for
Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center 50
Not applicableUnknownNCT06109233
What this trial is testing

A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment

Who this might be right for
Multiple MyelomaMinimal Residual Disease
FengYan Jin 80
Testing effectiveness (Phase 2)Looking for participantsNCT06505369
What this trial is testing

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
North Estonia Medical Centre 50
Testing effectiveness (Phase 2)Looking for participantsNCT03509961
What this trial is testing

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Pediatric Transplantation & Cellular Therapy Consortium 95
Not applicableLooking for participantsNCT06149910
What this trial is testing

Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

Who this might be right for
Multiple MyelomaMultiple Myeloma Without Mention of Remission
All4Cure 450
Testing effectiveness (Phase 2)Looking for participantsNCT06993675
What this trial is testing

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Who this might be right for
Multiple Myeloma
Noffar Bar 50